Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + valsartan
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telmisartan and valsartan are both angiotensin II receptor blockers (ARBs) used in the management of hypertension. This specific entry refers to the comparative clinical evaluation of these two agents, notably in trials sponsored by Boehringer Ingelheim (such as NCT00153010) to demonstrate the sustained blood pressure-lowering effect of telmisartan (Micardis) compared to valsartan (Diovan), particularly during the final hours of the dosing interval or after a missed dose. Telmisartan is characterized by a high affinity for the AT1 receptor and a long terminal elimination half-life of approximately 24 hours, which distinguishes it from other ARBs like valsartan. Both drugs function by selectively antagonizing the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II, thereby reducing peripheral vascular resistance and blood pressure.
- Brand names
- MicardisDiovan
- Other names
- telmisartanvalsartan
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on telmisartan + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + valsartan.